Tridem Bioscience Enrolls First Patients in Phase Ib Clinical Study of its Lead Vaccine Candidate for Parkinson’s Disease
Advancing a differentiated active immunotherapy approach targeting alpha-synuclein in Parkinson's disease; first human data confirm unique translational potentia...



















